Publications by authors named "M Serbes"
Article Synopsis
- The study analyzes data from the CF Registry of Turkey to measure the rate of decline in pulmonary function (ppFEV1) among cystic fibrosis patients and identifies risk factors related to this decline.
- It found that patients with more severe disease (ppFEV1 < 40) had poorer nutritional status and a higher prevalence of chronic Pseudomonas aeruginosa infection compared to those with better lung function.
- The results emphasize the need for regular monitoring of patients with normal initial ppFEV1 and early treatment for P. aeruginosa infections, highlighting the crucial role of proper nutrition in managing cystic fibrosis.
Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs.
View Article and Find Full Text PDFAim: In this cross-sectional descriptive study, we aimed to determine the clinical characteristics of children admitted to a tertiary hospital with asthma exacerbations in a city in southern Turkey where aeroallergens are common and to determine how these characteristics affect the severity of exacerbations.
Methods: Data from a cross-sectional analysis of children with asthma exacerbations who were followed up at the Cukurova University Medical Faculty Pediatric Emergency Department (ED) and Pediatric Allergy & Immunology inpatient clinic were retrospectively analyzed. The study included 106 children who were diagnosed with asthma and did not have any additional comorbidities.
Article Synopsis
- * The study analyzed 15 patients diagnosed with GS2 from 2017 to 2022, finding that 73.3% developed HLH, with various presentations including central nervous system involvement.
- * Treatment included using the HLH-2004 protocol and hematopoietic stem cell transplantation (HSCT); while those who had HSCT survived, three patients without suitable donors unfortunately did not.
The childhood interstitial lung diseases (chILD) Turkey registry (chILD-TR) was established in November 2021 to increase awareness of disease, and in collaboration with the centers to improve the diagnostic and treatment standards. Here, the first results of the chILD registry system were presented. In this prospective cohort study, data were collected using a data-entry software system.
View Article and Find Full Text PDF